ABSENCE OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOCYTIC LEUKEMIA (CML) QATARI PATIENTS ON IMATINIB MESYLATE (IM) TREATMENT

被引：0
|
作者：
Al-Dewik, I. [1 ]
Jewell, P. [2 ,3 ]
Elayoubi, R. [1 ]
Morsi, M. [4 ]
机构：
[1] Hmc Al Amal Oncol Ctr, Doha, Qatar
[2] Kingston Univ, London, England
[3] St Georges Univ, London, England
[4] Aquamed ME, Res & Educ Dept, Doha, Qatar
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1313
引用
收藏
页码：532 / 532
页数：1
相关论文
共 50 条
  • [21] Management of imatinib mesylate-resistances induced by BCR-ABL mutations in chronic myelogenous leukemia
    Nicolini, Franck-Emmanuel
    Ducastelle, Sophie
    Corm, Selim
    HEMATOLOGIE, 2007, 13 (06): : 457 - 464
  • [22] BCR-ABL Kinase Domain Mutations Exist in Few Imatinib Treated Chronic Myeloid Leukemia (CML) Patients Exhibiting Stable Cytogenetic and Hematologic Responses
    Akram, Afia Muhammad
    Akhtar, Tanveer
    Chaudhary, Asma
    Shahzad, Muhammad Mudassar
    Khalid, Ahmad Mukhtar
    Sajid, Nadia
    Sabar, Muhammad Farooq
    Iqbal, Zafar
    BLOOD, 2018, 132
  • [23] Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients
    Qin, YaZhen
    Chen, ShanShan
    Jiang, Bin
    Jiang, Qian
    Jiang, Hao
    Li, JinLan
    Li, LingDi
    Lai, YueYun
    Liu, YanRong
    Huang, XiaoJun
    ANNALS OF HEMATOLOGY, 2011, 90 (01) : 47 - 52
  • [24] Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India
    Kagita, Sailaja
    Uppalapati, Srihari
    Jiwatani, Sangeeta
    Linga, Vijay Gandhi
    Gundeti, Sadasivudu
    Nagesh, Narayana
    Digumarti, Raghunadharao
    TUMOR BIOLOGY, 2014, 35 (07) : 7187 - 7193
  • [25] Quantitative analyses of BCR-ABL mutations associated with imatinib treatment in CML
    Gruber, F
    Hansen, HH
    Olsen, M
    Eggen, L
    Skogen, B
    Gedde-Dahl, T
    Lundan, T
    Porkka, K
    Simonsson, B
    Markevdrn, B
    Wadenvik, H
    Stenke, L
    BLOOD, 2005, 106 (11) : 566A - 566A
  • [26] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
    Bintoro, S. U. Y.
    Amrita, P. N. A.
    Joewarini, E.
    Suryohusodo, P.
    Soebandiri, S.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58
  • [27] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    Pfeifer, H.
    Lange, T.
    Wystub, S.
    Wassmann, B.
    Maier, J.
    Binckebanck, A.
    Giagounidis, A.
    Stelljes, M.
    Schmalzing, M.
    Duehrsen, U.
    Wunderle, L.
    Serve, H.
    Brueck, P.
    Schmidt, A.
    Hoelzer, D.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (07) : 1475 - 1481
  • [28] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    H Pfeifer
    T Lange
    S Wystub
    B Wassmann
    J Maier
    A Binckebanck
    A Giagounidis
    M Stelljes
    M Schmalzing
    U Dührsen
    L Wunderle
    H Serve
    P Brück
    A Schmidt
    D Hoelzer
    O G Ottmann
    Leukemia, 2012, 26 : 1475 - 1481
  • [29] BCR-ABL kinase domain mutations in chronic myeloid leukemia - Not quite enough to cause resistance to imatinib therapy?
    Lange, T
    Park, B
    Willis, SG
    Deininger, MWN
    CELL CYCLE, 2005, 4 (12) : 1761 - 1766
  • [30] The kinetics of BCR-ABL transcript levels in CML patients in chronic or accelerated phase during imatinib mesylate treatment.
    Klamova, H
    Moravcova, J
    Zmekova, V
    Voglova, J
    Faber, E
    BLOOD, 2003, 102 (11) : 325B - 326B
12345